ALXP
ALINT
Market cap525kUSD
Oct 28, Last price
0.07EUR
1D
19.05%
1Q
-64.10%
Jan 2017
-97.94%
IPO
-99.24%
Name
Integragen SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
IntegraGen S.A. provides advanced human genome analysis services to academic researchers and life science businesses across France. Their comprehensive genomic offerings include transcriptomics, epigenomics, DNA sequencing, next-generation sequencing (NGS) specifically for cancer research, and SNP genotyping. The company also delivers clinical research solutions, such as clinical-grade sequencing and pharmacogenomic studies, in addition to supporting fundamental human genetic investigations. For agricultural applications, IntegraGen offers agrigenomic services covering crop and livestock genotyping, as well as high-throughput sequencing for these domains. Their microbial genomics division conducts whole-genome microbial sequencing and transcriptomics. IntegraGen further develops a suite of sophisticated bioinformatics tools: MERCURY is an online platform for oncology, designed to transform raw high-throughput sequencing data into molecular reports for translational and clinical research. SIRIUS, a cloud-based software, empowers researchers to analyze whole genome, whole exome, and gene panel sequencing information. Galileo is another cloud application that enables dynamic exploration of RNA-Seq expression data. Finally, GeCo, their genomic consulting service, provides researchers access to expert biostatisticians and bioanalysts. Founded in 2000 and headquartered in Évry, France, IntegraGen S.A. is a subsidiary of OncoDNA SA.
Key people
Laurence Riot Lamotte
Director of Administration and Finance · since 2011
Larry Yost
Chief Executive Officer - Integragen Inc
Emmanuel Martin
Director Sales & Marketing for the Services Business Unit · since 2006
Francis Rousseau
Director of Genomics
Benoit Adelus
Director · since 2009
Philippe Boucheron
Director, representing CDC Entreprises
Bernard Courtieu
Chairman of the Board, Chief Executive Officer · since 2007
Cyril Harfouche
Director
Louis Nisbet
Director, representing Kurma Life Sciences Partners
Chantal Parpex
Director, representing CDC Innovation · since 2011
Gerald Wagner
Director · since 2005
Headquarters & legal address
5 RUE HENRI DESBRUERES
GENOPOLE CAMPUS 1
EVRY-COURCOURONNES 91000
FR
GENOPOLE CAMPUS 1
EVRY-COURCOURONNES 91000
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT | |